Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 490-496, Vol. 7, No. 3
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Specificity and Prevalence of Natural Bovine
Anti-Alpha Galactosyl (Gal
1-6Glc or Gal
1-6Gal)
Antibodies
Yawei
Ni,1,*
Robert
Powell,2
Debra D.
Turner,2 and
Ian
Tizard2
Carrington Laboratories Inc., Irving, Texas
75062,1 and Department of Veterinary
Pathobiology, College of Veterinary Medicine, Texas A&M University,
College Station, Texas 778432
Received 21 October 1999/Returned for modification 24 January
2000/Accepted 10 March 2000
 |
ABSTRACT |
Immunity against the carbohydrate components of microorganisms
mediated by antibodies is an important part of host defenses. Humans
and closely related primates, but not other mammals, possess natural
anti-Gal
1-3Gal antibodies which also, although less avidly, react
with melibiose (Gal
1-6Glc). Using an enzyme-linked immunosorbent assay (ELISA) with melibiose-bovine serum albumin as an antigen, we
analyzed bovine anti-alpha galactosyl antibodies with respect to
specificity and distribution in individual animals. Inhibition assays
showed that melibiose was the strongest inhibitor, followed equally by
stachyose (Gal
1-6Gal
1-6Glc
1-2Fru) and raffinose (Gal
1-6Glc
1-2Fru) and then by Gal
1-6Gal, Gal, and
Gal
1-2Gal. Others, including Gal
1-3Gal and Gal
1-4Gal, only
exhibited minor inhibition. Thus, these bovine anti-alpha galactosyl
antibodies appeared to preferentially react with Gal
1-6Glc or
Gal
1-6Gal. The distinction of this specificity from that
(Gal
1-3Gal) of human antibodies was further demonstrated by the poor
reaction of bovine serum to the Gal
1-3Gal antigen in comparison to
human serum. All 27 healthy bovine serum samples of the three age
groups (newborn, calf, and adult) tested contained such antibodies with titers increasing with age. The antibodies purified by affinity chromatography using a melibiose-agarose column were mainly of the
immunoglobulin G (IgG) isotype with a concentration of >23 µg/ml in
most samples. IgG1 was found to be the primary antimelibiose IgG
isotype in all age groups by isotype-specific ELISA, but a significant
increase in IgG2, an isotype more related to innate immunity, was
observed in calves and adults, compared to newborns. The purified
antibodies reacted with the type II bovine strain of
Streptococcus agalactiae, a common pathogen of bovine
mastitis. Thus, these anti-Gal
1-6Glc or Gal
1-6Gal antibodies in
cattle might be involved in defense against microbes bearing this or the related epitopes.
 |
INTRODUCTION |
Humans and closely related mammals
possess natural anti-alpha galactosyl (Gal
1-3Gal) antibodies
(22). It is suggested that these human antibodies are
developed in response to normal bacterial flora in the intestine
(8) in a way similar to the blood group antigen-specific
antibodies (34). The anti-alpha galactosyl (Gal
1-3Gal)
antibodies are found in humans, apes, and Old World monkeys but not in
New World monkeys and other mammals (7, 9). This is
consistent with the fact that humans, apes, and Old World monkeys lack
a functional alpha (1-3) galactosyltransferase (14, 19) and
therefore do not possess the Gal
1-3Gal structure on their tissues.
The opposite is true in other mammalian species, including cattle
(13, 18), and the Gal
1-3Gal structure is therefore a self
antigen in these species.
The human anti-Gal
1-3Gal antibodies have an unusually high titer,
accounting for as much as 1% of total serum immunoglobulin G (IgG) (20 to 100 µg/ml) (5). They have been suggested to play an
important role in innate immunity. They are responsible for
inactivation of retrovirus and other enveloped viruses of animal origin
by human serum (21, 28, 32) and rejection of pig-to-human
xenografts (23). They may also be involved in preventing
microbial and parasite infections (1, 30).
Although the human anti-alpha galactosyl antibodies react most avidly
with the Gal
1-3Gal structure, they also react strongly with
melibiose (Gal
1-6Glc) (6, 35). As a result, melibiose has
been used as a ligand for the affinity purification of these human
antibodies. Recently, antimelibiose antibodies have been detected in
cattle and chickens (26, 27), suggesting that there are
similar anti-alpha galactosyl antibodies in animals. However, their
specificity and distribution have not been extensively studied and no
comparison has been made with the Gal
1-3Gal epitope. Here we report
the characterization of the specificity and distribution of the bovine
antimelibiose antibodies and their potential involvement in host
defense against microorganisms.
 |
MATERIALS AND METHODS |
Bacteria.
Streptococcus agalactiae types II (ATCC
27541), IV (ATCC 49446), and V (ATCC 700048) were obtained from the
American Type Culture Collection. Type II is a bovine strain isolated
from a cow with mastitis, whereas types IV and V are strains from
humans. A clinical isolate of S. agalactiae obtained from
the milk of a cow suspected of having mastitis and designated 5247 was
provided by the Texas Veterinary Medical Diagnostic Laboratory (College Station). Escherichia coli (ATCC 25922 and ATCC 35215),
Staphylococcus aureus (ATCC 29213 and ATCC 25923), and
Pseudomonas aeruginosa (ATCC 27853) were also used. All
bacteria were maintained on blood agar. They were cultured in tryptose
broth for 24 h at 37°C before used in dot blot analysis.
Serum samples.
One fetal, three newborn (1 to 10 days old),
and five calf (~6 months old) bovine pooled serum samples were
obtained from Gibco-BRL (Grand Island, N.Y.). Nineteen adult sera were
obtained from cows at ages of 1 to >10 years in the Veterinary
Medicine Park, Texas A&M University. All adult samples were collected
in October 1996. An older sample collected in May of 1992 from one cow
was also used and designated 16-1. The new sample from this same cow
was designated 16-2. All serum samples were stored at
20°C. A
pooled adult sample was made by mixing equal volumes of individual
adult samples, excluding samples 1, 6, 12, and 16-1 because of the
limited amounts available. Two pooled adult human serum samples were
used, one (I) from Sigma Chemical Co. (St. Louis, Mo.) and another (II)
from Scantibodies Lab, Inc. (Santee, Calif.).
ELISA.
An indirect enzyme-linked immunosorbent assay (ELISA)
was used to measure serum antimelibiose antibodies. The assay was
performed in a reagent excess manner; both the antigen and secondary
antibody were used in excess amounts as determined by titration assays. Plates (NUNC, Inc., Naperville, Ill.) were coated overnight at 4°C
with melibiose (Gal
1-6Glc)-bovine serum albumin (BSA; Sigma Chemical
Co.) or Gal
1-3Gal-BSA (V-LAB, Covington, La.) at a concentration of
5 µg/ml in 50 mM carbonate buffer (pH 9.6) (100 µl/well). Plates were washed three times with wash buffer (phosphate-buffered saline [PBS] with 0.02% NaN3) and then blocked for 1 h
with dilution buffer containing 3% BSA (gamma globulin free; Sigma
Chemical Co.), 0.05% Tween 20, and 0.02% NaN3 in PBS.
Serum samples diluted in the same buffer were added to the plates (100 µl/well) and incubated at room temperature for 2 h. Following
washing as described above, affinity-purified alkaline
phosphatase-conjugated anti-human IgG whole molecule (Sigma Chemical
Co.), anti-bovine IgG whole molecule (Sigma Chemical Co.), or alkaline
phosphatase-conjugated anti-bovine IgM heavy (µ)-chain antibodies
(KPL, Gaithersburg, Md.) at a 1:1,000 dilution were added (100 µl/well) and incubated at room temperature for 1 h. After being
washed, each well on the plate received 100 µl of the substrate
p-nitrophenylphosphate prepared in accordance with the
instructions from the manufacturer (Pierce, Rockford, Ill.). The
reaction was stopped after a 10-min incubation by addition of 50 µl
of 2 M NaOH. Optical density (OD) at 405 nm was determined using a
Dynatech microplate reader (MR600).
For inhibition assays, sugars were first serially diluted twofold in
the dilution buffer. Each dilution was then mixed with an equal volume
of a diluted reference serum sample (calf sample 2). The mixture was
then kept at room temperature for 1 h before being added to the
plates. The remaining steps were the same as those described above. The
inhibition efficiencies of various sugars were compared by determining
the lowest concentrations that gave a 50% reduction in OD. The
monosaccharides, disaccharides, and oligosaccharides used were obtained
from Sigma Chemical Co., except for Gal
1-3Gal, which was obtained
from V-LAB.
Statistical analysis of ELISA data.
A pooled calf serum
sample (no. 2) was used as a reference for determining titers of
individual samples. The titration endpoint was arbitrarily chosen as
the highest serum dilution that gave an OD twofold higher than that of
the background (fetal bovine serum). The endpoint was assigned as 1 titer unit/100 µl. This gave calf sample 2 a unit range of 1 (1:640) to 64 (1:10). The OD values were plotted against the logarithm
of the titer units. A linear fit was made, and the log unit value of
each sample was obtained by extrapolating against the regression line.
The titer units per 0.1 ml of serum were calculated by an anti-log
transformation, followed by multiplication with the sample dilution.
All samples were tested at a 1:80 or 1:160 dilution so that OD values
were within the range of the standard curve. The geometric means of different age groups were compared by the unpaired Student t test.
Measurement of anti-alpha galactosyl IgA, IgG1, and IgG2.
Anti-alpha galactosyl IgG1, IgG2, and IgA were measured by an indirect
ELISA using affinity-purified anti-bovine IgA, IgG1, and IgG2
antibodies conjugated to horseradish peroxidase (Bethyl Laboratories,
Montgomery, Tex.). The ELISA was performed as described above in a
reagent excess manner. The conjugates or secondary antibodies were used
at a 1:1,000 dilution. All serum samples were diluted 1:40.
Tetramethylbenzidine (Pierce) was used as the substrate. The reaction
was stopped after a 30-min incubation by addition of 100 µl of 2 M
H2SO4. OD at 450 nm was determined using a
Dynatech microplate reader (MR600).
Affinity chromatography.
A 10-ml column of melibiose-agarose
(Sigma Chemical Co.) was used for isolation of the bovine antimelibiose
antibodies. The column was first washed with 100 ml of TN buffer (20 mM
Tris, 150 mM NaCl, pH 7.4) containing 0.02% NaN3. Bovine
serum (20 ml) mixed with an equal volume of the same buffer was loaded
onto the column at a rate of 15 ml/h. The column was then washed with 200 ml of the buffer, and bound proteins were eluted with 200 mM
melibiose in the same buffer. One-milliliter fractions were collected.
Those fractions containing detectable proteins were pooled, dialyzed
against TN buffer, and concentrated with polyvinylpyrrolidone (molecular weight, 360,000; Sigma Chemical Co.). Protein concentrations were determined by the bicinchoninic acid protein assay (Pierce).
Gel electrophoresis and immunoblotting.
Electrophoretic
analysis of isolated proteins was carried out under denaturing
conditions as described previously (17). Proteins were
detected by Coomassie blue staining.
For immunoblot analysis, proteins were blotted from the gel onto
Immobilon P polyvinylidene difluoride membranes. Blotted
membranes were
first blocked at room temperature in TN buffer
(25 mM Tris, 150 mM
NaCl, pH 7.4) containing 3% BLOTTO and 0.05%
Tween 20 for 2 h.
They were then probed at room temperature for
1 h with the
affinity-purified, alkaline phosphatase-conjugated
anti-bovine IgG
whole molecule or anti-bovine IgM heavy (µ) chain
in TN buffer
containing 1% BLOTTO and 0.05% Tween 20. After washing
with TN buffer
containing 0.05% Tween 20, membranes were developed
with the substrate
BCIP (5-bromo-4-chloro-3-indolylphosphate)-nitroblue
tetrazolium,
obtained from Sigma Chemical
Co.
Dot blot assay.
A dot blot assay was used to determine if
the purified bovine antimelibiose antibodies reacted with bacteria.
Bacteria were grown in tryptose broth at 37°C for 24 h. They
were washed three times with PBS and suspended in PBS at
108/ml. Bacteria were killed by incubation at 60°C for
1 h. One and one-half microliters of the killed-bacterial
preparations were spotted onto dry cellulose membranes and air dried.
Coomassie blue staining was performed to ascertain that the amount of
bacteria attached to the membrane was consistent. The membranes were
blocked with 3% BSA and 0.05% Tween 20 in PBS at room temperature for 2 h. They were then probed at room temperature for 1 h with
purified bovine antimelibiose antibodies (1 µg/ml) in PBS containing
1% BSA and 0.05% Tween 20. Melibiose was used as an inhibitor at a
concentration of 10 mM. The remaining steps with affinity-purified, alkaline phosphatase-conjugated anti-bovine IgG whole molecule and
BCIP-nitroblue tetrazolium substrate were the same as those described above.
 |
RESULTS |
The bovine anti-alpha galactosyl antibodies in serum were measured
with an ELISA using melibiose (Gal
1-6Glc)-BSA as an antigen (see
Materials and Methods). The serum titration curves of seven serum
samples, two pooled newborn, two pooled calf, two adult, and one pooled
adult, are presented in Fig. 1. They were
parallel to each other, suggesting that the measured antibodies reacted against the same epitope. Calf sample 2, a pooled serum sample, was
used as the reference sample and included in all assays. The specificity of this assay was confirmed by inhibition assays with melibiose (see below).
Specificity of bovine anti-alpha galactosyl antibodies.
Inhibition assays with various monosaccharides, disaccharides, and
oligosaccharides were used to determine the specificity of the bovine
anti-alpha galactosyl antibodies. The results are shown in Table
1 and Fig.
2. Based on the lowest concentrations showing a 50% reduction in OD, melibiose was the strongest
inhibitor, followed equally by stachyose
(Gal
1-6Gal
1-6Glc
1-2Fru) and raffinose (Gal
1-6Glc
1-2Fru) and then almost equally by Gal
1-6Gal,
Gal, and Gal
1-2Gal (Table 1). Others, including Gal
1-3Gal,
Gal
1-4Gal, and lactose (Gal
1-4Glc), exhibited only minor
inhibition (Table 1). Since the Gal
1-6Glc or Gal
1-6Gal structure
was present at the nonreducing end of stachyose or raffinose, these
results suggest that these bovine anti-alpha galactosyl antibodies
preferentially react with galactose in the
1-6 linkage (Gal
1-6Glc
or Gal
1-6Gal).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Inhibition of the reaction of bovine anti-alpha
galactosyl antibodies to melibiose-BSA antigen by various sugars
|
|
To compare the specificity of these bovine anti-alpha galactosyl
antibodies with those of human antibodies, Gal

1-3Gal-BSA
was used
as an antigen in a comparison with the melibiose (Gal

1-6Glc)-BSA
antigen. The assays with these two antigens were not standardized
with
respect to the exact amount of antigen used to coat each
well but
rather performed under the same conditions to provide
a relative
comparison. It was found that the bovine serum reacted
much more
strongly to melibiose than to the Gal

1-3Gal antigen,
with an average
OD (melibiose/Gal

1-3Gal) ratio of 2.2 to 3.0
over a dilution range
of 1:5 to 1:160 (Fig.
3A). This is
consistent
with the observation that Gal

1-3Gal was a poor inhibitor
of the
bovine antibodies when reacting to melibiose-BSA (Table
1 and
Fig.
2). On the other hand, human antibodies reacted with these
two
antigens to a similar degree, with an average OD
(melibiose/Gal

1-3Gal)
ratio of 1.2 to 1.5 over the same dilution
range (Fig.
3B). Compared
with bovine antibodies, the human antibodies
exhibited a weaker
reaction with the melibiose antigen (Fig.
3A and B)
but a stronger
reaction with Gal

1-3Gal (Fig.
3A and B). These
results further
indicate that bovine anti-alpha galactosyl antibodies
are distinct
from those in humans with respect to antigen specificity.
It seems
that the specificity of bovine antibodies is more restricted
to
melibiose compared to that of human antibodies to Gal

1-3Gal.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Specificity comparison of human and bovine anti-alpha
galactosyl antibodies. Panels: A, bovine sera (calf sample 2 and pooled
adult sample); B, human sera (samples I and II). Each serum sample was
tested against both antigens on the same plate, and each plate was used
for two serum samples (one bovine and one human).
|
|
Presence of bovine anti-alpha galactosyl antibodies in different
age groups.
Twenty-seven bovine serum samples of three age groups
were tested (Fig. 4). They included 3 pooled newborn (1 to 10 days old) samples, 5 pooled calf (~6 months
old) samples, and 19 adult (>1 year old) samples. All of them,
including those from the newborn, contained the antimelibiose
antibodies. The antibody titers gradually increased from newborn to
adult samples (Fig. 4), although the differences were not statistically
significant. Titers in individual adult samples varied widely, with an
average of 754 and a standard deviation of 546 (Fig. 4), although they
exhibited a normal distribution (95% of the values were within the
mean ± 2 standard deviations). Those at an age of 5 to 9 years
(no. 12 to 16-1) exhibited the highest titers. It was noted that the
titer of the freshly obtained sample (16-2) was fourfold lower than
that of the one (16-1) obtained 4 years ago. By 1996, this cow was more
than 10 years old.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Presence of anti-alpha galactosyl antibodies in bovine
serum samples. Samples were tested at a 1:80 or 1:160 dilution. The
titer unit was obtained by extrapolation against the regression curve
of the reference sample (calf sample 2; see Materials and Methods). The
horizontal bars indicate the average titers for each age group, and the
error bars show the standard deviations.
|
|
Adult serum sample 2 had the lowest titer. In light of the lack of a
known negative serum sample, a sugar inhibition assay
was performed to
ascertain that this sample was, indeed, positive.
Melibiose at 3 mM
produced a more than 50% inhibition of this
sample, but lactose at 12 mM did not (data not shown). This confirms
that this sample did contain
the antimelibiose
antibodies.
Only weak reactions were detected when the anti-bovine IgM (µ chain)
conjugate was used; all sample ODs were less than twofold
higher than
the background. This suggests that the bovine antimelibiose
antibodies
are mainly of the IgG
isotype.
Purification of bovine anti-alpha galactosyl antibodies.
The
anti-alpha galactosyl antibodies were purified by affinity
chromatography using melibiose-agarose. Gel electrophoretic analysis of
proteins eluted from the column with melibiose showed that the IgG
heavy chain was the dominant band (Fig.
5, lane 1). The antibody heavy and light
chains were identified by immunoblotting (Fig. 5, lanes 2 and 3). The
IgM heavy chain was barely detectable, compared to the IgG heavy chain
(Fig. 5). This observation is consistent with the results described
above, suggesting that the bovine antimelibiose antibodies are mainly
of the IgG isotype. The protein close to 200 kDa (Fig. 5, lanes 1 and
2) was most likely the undenatured IgG whole molecule, since it reacted
with anti-IgG whole molecule antibody (Fig. 5, lane 2) but not with anti-IgM heavy (µ)-chain antibody (Fig. 5, lane 3).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
Gel electrophoresis and immunoblotting analysis of
bovine serum proteins eluted from the melibiose-agarose column. Lanes:
1, proteins stained with Coomassie blue; 2, proteins probed with
alkaline phosphatase-conjugated anti-bovine IgG whole molecule; 3, proteins probed with alkaline phosphatase-conjugated anti-bovine IgM
heavy (µ) chain. The open arrowheads indicate the IgG whole molecule,
the closed arrowheads indicate the IgM heavy chain, the empty arrows
indicate the IgG heavy chain, and the filled arrows indicate the light chain. Molecular size standards in kilodaltons are indicated on
the left.
|
|
Out of 20 ml of the reference serum sample (calf sample 2), an average
of 444 µg of antibodies was obtained in two separate
experiments (444 and 475 µg), giving a concentration of 23 µg/ml
in the serum. The
titer (681) of calf sample 2 was below the average
(713) of all
samples, and so, most of the samples likely have
a higher concentration
of such
antibodies.
Anti-alpha galactosyl IgA, IgG1, and IgG2.
The anti-alpha
galactosyl IgA, IgG1, and IgG2 antibodies were examined using 2 pooled
newborn samples, 2 pooled calf samples, and 1 pooled adult sample along
with 10 individual adult samples. The anti-alpha galactosyl antibody
was primarily of the IgG1 isotype in all samples, except for two adult
samples, 7 and 10, which had more IgG2 than IgG1 (Fig.
6A and B). However, it was noted that the
IgG2 level was significantly increased in calves and adults compared to
newborns (P < 0.05). In fact, the increase in IgG2
accounted for 81% of the total IgG increase in calves and adults. IgA
was present in all of the samples, and its level was much higher in
newborns than in calves or adults (Fig. 6A and B).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 6.
Measurement and comparison of anti-alpha galactosyl IgA,
IgG1, and IgG2 responses. The anti-alpha galactosyl IgA, IgG1, and IgG2
antibodies were measured using class- or isotype-specific antibodies
conjugated to horseradish peroxidase as described in Materials and
Methods. All sera were diluted 1:40. The serum sample numbers
correspond to those in Fig. 4. Panels: A, Anti-alpha galactosyl IgA,
IgG1, and IgG2 levels expressed as direct OD values; B, Anti-alpha
galactosyl IgA, IgG1, and IgG2 levels expressed as percentages.
|
|
Reaction of purified bovine anti-alpha galactosyl antibodies with
S. agalactiae.
Many bacteria, including
Streptococcus spp., are known to have immunoreactive
terminal galactose residues in capsular polysaccharides (2,
20). S. agalactiae and group B streptococci are major causes of human neonatal infections (24) and also bovine
mastitis (16). To determine if the bovine anti-alpha
galactosyl antibodies react with these bacteria and others, three
American Type Culture Collection S. agalactiae strains
(serotypes II, IV, and V) and a bovine S. agalactiae
clinical isolate (5247) were tested in a dot blot test along with
strains of E. coli, S. aureus, and P. aeruginosa. The type II S. agalactiae strain is an
isolate from a bovine with mastitis, whereas the type IV and V strains are from humans. The results of the dot blot tests showed that these
bovine antibodies reacted with the type II bovine strain and the
clinical bovine isolate (5247) (Fig. 7A).
No reaction was detected with the type IV or V human strain (Fig. 7A)
or with the E. coli, S. aureus, and P. aeruginosa strains tested (data not shown). The reaction with
bovine strains was inhibited by melibiose (Fig. 7B).

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 7.
Reaction of bovine anti-alpha galactosyl antibodies with
S. agalactiae. Bacteria spotted onto the membrane were
probed with bovine anti-alpha galactosyl antibodies in the absence (A)
or in the presence (B) of melibiose (10 mM).
|
|
 |
DISCUSSION |
The present experiments demonstrated that cattle possess an
anti-alpha galactosyl antibody with a serum concentration close to that
of human anti-Gal
1-3Gal antibodies (20 to 100 µg/ml). However, the
specificity of these bovine antibodies is distinctly different from
that of human antibodies. The bovine anti-alpha galactosyl antibodies
preferentially reacted with the galactose in
1-6 linkage, i.e.,
Gal
1-6Glc or Gal
1-6Gal.
Stachyose and raffinose are the second strongest inhibitors (next to
melibiose) (Table 1). It is not known why stachyose (Gal
1-6Gal
1-6Glc
1-2Fru) and raffinose (Gal
1-6Glc
1-2Fru)
are less efficient inhibitors than melibiose, especially the latter, which has a structure identical to that of melibiose (Gal
1-6Glc) at
the nonreducing end. It may be that the third sugar affects the
binding; i.e., the third sugar found in stachyose and raffinose may not
be the right one for the optimal binding of these antibodies. Alternatively, it could be due to the fact that larger molecules are
simply less efficient competitors than the smaller ones bearing the
same functional domain. Similar observations have been made with human
anti-alpha galactosyl antibodies (35).
Gal
1-6Gal and Gal
1-2Gal were moderate inhibitors (Table 1),
suggesting that a significant reaction may also be found with these two
structures. On the other hand, Gal
1-3Gal, Gal
1-4Gal, and lactose
(Gal
1-4Glc) were weak inhibitors. Together, it seems that these
bovine antibodies favor the linkage positions more than the anomeric
configuration of the linkage since Gal
1-6Gal is a more efficient
inhibitor than Gal
1-3Gal and Gal
1-4Gal.
The lack of a strong reaction of bovine anti-alpha galactosyl
antibodies to the Gal
1-3Gal structure is consistent with the fact
that the Gal
1-3Gal epitope is a self antigen in animals, including
cattle, due to the presence of alpha (1-3) galactosyltransferase (13). By the same token, cattle might lack the Gal
1-6Glc
or Gal
1-6Gal structure in their tissues; i.e., they might lack an alpha (1-6) galactosyltransferase. Whether humans have such an enzyme
also remains to be determined, although the Gal
1-6Gal structure has
been reported in human tumor cells (10, 15).
The origin of these bovine antibodies is not known. They could develop
in response to any environmental agents bearing this epitope. The
positive reaction of these antibodies with bovine S. agalactiae suggests that responses to bacteria, either pathogenic or nonpathogenic, can be one of the sources, although a positive reaction itself does not necessarily prove the possession of an identical epitope (Gal
1-6Glc or Gal
1-6Gal) by the bacteria. S. agalactiae is a primary pathogen of bovine mastitis and
is of major economic concern in the dairy industry (16). It
is also the leading cause of human neonatal mortality and morbidity (24). Although all serotypes can be found in both human and animals, serotype II is one of the most frequently isolated serotypes (II and III) in bovine mastitis cases (12, 31).
Structures of capsular polysaccharides of bovine S. agalactiae have not been elucidated. Studies on the human strains
of all six serotypes showed that there is no terminal
(1-6)-linked
galactose residue present in the capsular polysaccharides (11,
33). However, terminal galactose residues in
1-6 linkage are
present in the type II strain (11). Gal
1-6Gal was found
to be a moderate inhibitor of these bovine anti-alpha galactosyl
antibodies. Thus, it seems consistent with the finding that these
bovine antibodies reacted negatively with the human type IV and V
S. agalactiae strains but positively with the bovine type II
strain. Studies with S. cricetu and S. sobrinus
have also shown that only certain serotypes possess the terminal
galactose residues in a particular linkage (2, 20).
Bovine antimelibiose antibodies are clearly present in newborns and are
most likely from the mother's colostrum. The titers of these
antibodies varied widely in adults, which may reflect various degrees
of exposure to microorganisms bearing this epitope or the related
epitopes. It was noted that among the adults (>1 year old), those 5 to
9 years old exhibited the highest titers. Furthermore, the titer may
vary in an individual at different times, as shown with two samples
(16-1 and 16-2) collected 4 years apart from the same cow. The titer of
the second sample (16-2), collected when the cow was >10 years old,
was severalfold lower than that of the first one (16-1). This was not
the case when antimannan (yeast) antibodies were measured in the same
samples; the titer in sample 16-2 was actually higher than that in
sample 16-1 (25).
There are two IgG isotypes in cattle, IgG1 and IgG2 (3).
IgG2 may be further divided into IgG2a and IgG2b. IgG1 was found to be
the primary anti-alpha galactosyl IgG in newborns, calves, and adults.
IgG1 is the major antibody in bovine serum, with an IgG1/IgG2 ratio of
1.2:1 (3). In cattle, there is no antibody transfer through
the placenta and newborns obtain maternal antibodies through colostrum.
IgG1 is also the major antibody in the colostrum (IgG1/IgG2 ratio,
16:1) and in milk (IgG1/IgG2 ratio, 116:1) (3). IgA is a
very minor immunoglobulin compared to IgG in both serum and colostrum,
although the IgA concentration in colostrum is significantly higher
than that in serum (colostrum IgA/serum IgA ratio, 15:1)
(3). This seems consistent with the finding that IgG1 was
the major anti-alpha galactosyl antibody in newborns, calves, and
adults. However, a significant increase in anti-alpha galactosyl IgG2
was observed in calves and adults, which accounted for 81% of the
total anti-alpha galactosyl IgG increase compared to newborns. Whereas
IgG1 has been, in general, found to be the primary IgG isotype induced
against infections or immunizations, the IgG2 response varies. Bovine
IgG2 appears to be more related to the innate immunity functions. Under
T-cell-independent conditions, gamma interferon increases the B-cell
production of IgG2 but not that of IgG1 (4) and only IgG2
has receptors on resting neutrophils and monocytes (29, 36).
Thus, an increase in the IgG2 level may enhance the innate immunity
response and the immune surveillance of the host against microorganisms
bearing this epitope (Gal
1-6Glc or Gal
1-6Gal) or a related epitope.
 |
ACKNOWLEDGMENTS |
We thank members of the Veterinary Medical Park of Texas A&M
University for collecting bovine serum samples and the Texas Veterinary
Medical Diagnostic Laboratory (College Station) for providing clinical
isolates of S. agalactiae. We also thank David N. McMurray
for reading the manuscript and helpful suggestions.
This work was supported by Carrington Laboratories Inc., Irving, Tex.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Carrington Lab,
c/o Department of Veterinary Pathobiology, College of Veterinary
Medicine, Texas A&M University, College Station, TX 77843. Phone: (409) 845-5599. Fax: (409) 862-2320. E-mail:
yni{at}vetmed.tamu.edu.
 |
REFERENCES |
| 1.
|
Avila, J. L., and A. Bretana.
1993.
Alpha-galactosyl epitope on Trypanosoma cruzi, Leishmania mexicana and L. braziliensis. Ultrastructural localization and possible role of antibodies against this epitope.
Acta Microsc.
2:43-54.
|
| 2.
|
Brown, T. A., and A. S. Bleiweis.
1979.
Chemical, immunochemical, and structural studies of the cross-reactive antigens of Streptococcus mutans AHT and B13.
Infect. Immun.
24:326-336[Abstract/Free Full Text].
|
| 3.
|
Butler, J. E.
1986.
Biochemistry and biology of ruminant immunoglobulins.
Prog. Vet. Microbiol. Immun.
2:1-153[Medline].
|
| 4.
|
Estes, D. M.,
W. C. Brown, and A. Hirano.
1998.
CD40 ligand-dependent signaling of bovine B lymphocyte development and differentiation.
Vet. Immunol. Immunopathol.
63:15-20[CrossRef][Medline].
|
| 5.
|
Galili, U.,
E. A. Rachmilewitz,
A. Peleg, and I. Flechner.
1984.
A unique natural human IgG antibody with anti-alpha-galactosyl specificity.
J. Exp. Med.
160:1519-1531[Abstract/Free Full Text].
|
| 6.
|
Galili, U.,
B. A. Macher,
J. Buehler, and S. B. Shohet.
1985.
Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1-3)-linked galactose residues.
J. Exp. Med.
162:573-582[Abstract/Free Full Text].
|
| 7.
|
Galili, U.,
M. R. Clark,
S. B. Shohet,
J. Buehler, and B. A. Macher.
1987.
Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3 Gal epitope in primates.
Proc. Natl. Acad. Sci. USA
84:1369-1373[Abstract/Free Full Text].
|
| 8.
|
Galili, U.,
R. E. Mandrell,
R. M. Hamadeh,
S. B. Shohet, and J. M. Griffiss.
1988.
Interaction between human natural anti- -galactosyl immunoglobulin G and bacteria of the human flora.
Infect. Immun.
56:1730-1737[Abstract/Free Full Text].
|
| 9.
|
Galili, U.,
S. B. Shohet,
E. Kobrin,
C. L. Stults, and B. A. Macher.
1988.
Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells.
J. Biol. Chem.
263:17755-17762[Abstract/Free Full Text].
|
| 10.
|
Gollogly, L., and V. Castronovo.
1996.
A possible role for the alpha 1-3 galactosyl epitope and the natural anti-gal antibody in oncogenesis.
Neoplasma
43:285-289[Medline].
|
| 11.
|
Jennings, H. J., and R. A. Pon.
1996.
Polysaccharides and glycoconjugates as human vaccines, p. 443-479.
In
S. Dumitriu (ed.), Polysaccharides in medical applications. Marcel Dekker, Inc., New York, N.Y.
|
| 12.
|
Jensen, N. E.
1985.
Epidemiological aspects of human/animal interrelationship in GBS.
Antibiot. Chemother.
35:40-48[Medline].
|
| 13.
|
Joziasse, D. H.,
J. H. Shaper,
D. H. Van Den Eijnden,
A. H. Van Tunen, and N. L. Shaper.
1989.
Bovine alpha 1-3-galactosyltransferase: isolation and characterization of a cDNA clone. Identification of homologous sequences in human genomic DNA.
J. Biol. Chem.
264:14290-14297[Abstract/Free Full Text].
|
| 14.
|
Joziasse, D. H.,
J. H. Shaper,
E. W. Jabs,
A. H. Van Tunen, and N. L. Shaper.
1991.
Characterization of an alpha1-3 galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene.
J. Biol. Chem.
266:6991-6998[Abstract/Free Full Text].
|
| 15.
|
Kawata, M.,
S. Sekiya,
H. Takamizawa,
T. Muramatsu, and K. Okumura.
1987.
Molecular properties of F9 embryoglycan recognized by a unique antibody in sera from patients with germ cell tumors.
Cancer Res.
47:2288-2294[Abstract/Free Full Text].
|
| 16.
|
Keefe, G. P.
1997.
Streptococcus agalactiae mastitis: a review.
Can. Vet. J.
38:429-437[Medline].
|
| 17.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 18.
|
Larsen, R. D.,
V. P. Rajan,
M. Ruff,
J. Kukowska-Latallo,
R. D. Cummings, and J. B. Lowe.
1989.
Isolation of a cDNA encoding a murine UDPgalactose: beta-D-galactosyl, 4-N-acetyl-D-glucosaminide alpha 1,3-galactosyltransferase: expression cloning by gene transfer.
Proc. Natl. Acad. Sci. USA
86:8227-8231[Abstract/Free Full Text].
|
| 19.
|
Larsen, R. D.,
C. A. Rivera-Marrero,
L. K. Ernst,
R. D. Cummings, and J. B. Lowe.
1990.
Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDPGA1: beta-D-Gal(1, 4)-GlcNAc-alpha (1,3)-galactosyltransferase cDNA.
J. Biol. Chem.
265:7055-7061[Abstract/Free Full Text].
|
| 20.
|
Ota, F.,
H. Kato, and K. Fukui.
1987.
Immunological study of cross-reactive polysaccharide antigens (types a, d, and h) of oral Streptococcus spp. with monoclonnal antibodies.
Infect. Immun.
55:266-268[Abstract/Free Full Text].
|
| 21.
|
Rother, R. P.,
W. L. Fodor,
J. P. Springhorn,
C. W. Birks,
E. Setter,
M. S. Sandrin,
S. P. Squinto, and S. A. Rollins.
1995.
A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.
J. Exp. Med.
182:1345-1355[Abstract/Free Full Text].
|
| 22.
|
Rother, R. P., and S. P. Squinto.
1996.
The alpha galactosyl epitope: a sugar coating that makes viruses and cells unpalatable.
Cell
86:185-188[CrossRef][Medline].
|
| 23.
|
Sandrin, M. S., and I. F. McKenzie.
1994.
Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies.
Immunol. Rev.
141:169-190[CrossRef][Medline].
|
| 24.
|
Schuchat, A.
1998.
Epidemiology of group B streptococcal disease in the United States: shifting paradigms.
Clin. Microbiol. Rev.
11:497-513[Abstract/Free Full Text].
|
| 25.
|
Srinivasan, A.,
Y. Ni, and I. Tizard.
1999.
Specifcity and prevalence of natural bovine antimannan antibodies.
Clin. Diagn. Lab. Immunol.
6:946-952[Abstract/Free Full Text].
|
| 26.
|
Sugii, S., and Y. Hirota.
1990.
Isolation and hemagglutinating activities of bovine immunoglobulins reactive with melibiose.
Jpn. J. Vet. Sci.
52:939-945.
|
| 27.
|
Sugii, S., and Y. Hirota.
1993.
Identification and characterization of the major carbohydrate-binding proteins in chicken serum as immunoglobulins.
J. Vet. Med. Sci.
55:125-128[Medline].
|
| 28.
|
Takeuchi, Y.,
C. D. Porter,
K. M. Strahan,
A. F. Preece,
K. Gustafsson,
F. L. Cosset,
R. A. Weiss, and M. K. Collins.
1996.
Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.
Nature
379:85-88[CrossRef][Medline].
|
| 29.
|
Tao, W.,
M. J. Corbett, and W. Pickett.
1995.
Monomeric bovine IgG2 is a potent stimulus for bovine neutrophils.
J. Leukoc. Biol.
58:203-208[Abstract].
|
| 30.
|
Travassos, L. R., and I. C. Almeida.
1993.
Carbohydrate immunity in American trypanosomiasis.
Springer Semin. Immunopathol.
15:183-243[Medline].
|
| 31.
|
Van Den Heever, L. W., and M. Erasmus.
1980.
Group B streptococcus comparison of Streptococcus agalactiae isolated from humans and cows in the Republic of South Africa.
J. South Afr. Vet. Assoc.
51:93-100.
|
| 32.
|
Welsh, R. M.,
C. L. Odonnell,
D. J. Reed, and R. P. Rother.
1998.
Evaluation of the Gal 1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.
J. Virol.
72:4650-4656[Abstract/Free Full Text].
|
| 33.
|
Wessels, M. R.,
J. L. DiFabio,
V. J. Benedi,
D. L. Kasper,
F. Michon,
J. R. Brisson,
J. Jelinkova, and H. J. Jennings.
1991.
Structural determination and immunochemical characterization of the type V group B streptococcus capsular polysaccharide.
J. Biol. Chem.
266:6714-6719[Abstract/Free Full Text].
|
| 34.
|
Wiener, A. S.
1951.
Origin of naturally occurring hemagglutinins and hemolysins.
J. Immunol.
66:287-295.
|
| 35.
|
Wieslander, J.,
O. Mansson,
K. Elisabeth,
A. Gabrielli,
H. Nowack, and R. Timpl.
1990.
Specificity of human antibodies against Gal 1-3Gal carbohydrate epitope and distinct from natural antibodies reacting with Gal 1-2Gal or Gal 1-4Gal.
Glycoconj. J.
7:85-100[CrossRef].
|
| 36.
|
Worku, M.,
M. J. Paape,
A. Di Carlo,
M. E. Kehrli, Jr., and W. W. Marquardt.
1994.
Modulation of Fc receptors for IgG on bovine polymorphonuclear neutrophils by interferon- through de novo RNA transcription and protein synthesis.
Am. J. Vet. Res.
55:234-238[Medline].
|
Clinical and Diagnostic Laboratory Immunology, May 2000, p. 490-496, Vol. 7, No. 3
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Aoki, K., Uchiyama, R., Yamauchi, S., Katayama, T., Itonori, S., Sugita, M., Hada, N., Yamada-Hada, J., Takeda, T., Kumagai, H., Yamamoto, K.
(2004). Newly Discovered Neutral Glycosphingolipids in Aureobasidin A-resistant Zygomycetes: IDENTIFICATION OF A NOVEL FAMILY OF GALA-SERIES GLYCOLIPIDS WITH CORE Gal{alpha}1-6Gal{beta}1-6Gal{beta} SEQUENCES. J. Biol. Chem.
279: 32028-32034
[Abstract]
[Full Text]